Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus

NCT03413722 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT03413722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03413722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus
Lead sponsor
University of Kansas Medical Center
Phase
Observational
Overall status
Completed
Start date
February 1, 2018
Completion date
October 1, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease